PD-1 therapy before surgery for advanced rectal cancer
Treatments studied
Part of Cancer clinical trials.
This trial tests giving PD-1 immunotherapy with chemotherapy before surgery for locally advanced rectal cancer. It aims to shrink the tumor and improve outcomes for patients who haven't had prior cancer treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a confirmed diagnosis of rectal adenocarcinoma (a type of rectal cancer).
- Your tumor is in the middle or lower rectum, within about 5 inches of the anal opening.
- Your cancer is locally advanced (spread into nearby tissues but not distant organs) and has certain high-risk features.
- Your tumor is microsatellite stable (MSS) type, which a special test can determine.
- You haven't had any prior cancer treatments like chemo, radiation, or immunotherapy.
- You are between 18 and 75 years old and are in good overall health (able to perform daily activities).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of chemotherapy and an immunotherapy drug (a PD-1 inhibitor) given before surgery for locally advanced rectal cancer. The goal is to see if this approach can improve outcomes compared to standard treatment.
This trial tests a combination of a cancer-killing virus (oncolytic virotherapy) and an immunotherapy drug (pembrolizumab) given before surgery for a certain type of rectal cancer. It aims to see if this approach helps shrink the tumor and improve outcomes for patients whose tumors have a normal DNA repair system (pMMR).
This trial studies giving long-course radiation and chemotherapy before surgery, plus an immunotherapy medicine (PD-1) to help the tumor shrink more. It’s for people with stage II or III rectal cancer that has not spread to distant organs.
This trial tests a medicine called PD-1 (a type of immunotherapy that helps your immune system fight cancer), sometimes with chemotherapy, before surgery for a certain type of colorectal cancer. It is for people whose tumors have a specific DNA repair problem (dMMR or MSI-H) and whose cancer has not spread to distant organs.
This study tests whether combining mFOLFOX6 chemotherapy with an immunotherapy drug (anti-PD-1) before surgery can shrink locally advanced rectal cancer. It is open to people whose tumors are mismatch repair proficient (pMMR) or microsatellite stable (MSS).
This study tests whether combining immunotherapy with a short course of radiation given before surgery can improve outcomes in early-stage rectal cancer. It may help the immune system work better against the tumor before it is removed.
Hear when a new Rectal Cancer Patients trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.